EP1009236A4 - Evaluierung, verabreichung und verwendung von mitteln zur behandlung vonherzerkrankungen - Google Patents

Evaluierung, verabreichung und verwendung von mitteln zur behandlung vonherzerkrankungen

Info

Publication number
EP1009236A4
EP1009236A4 EP98934656A EP98934656A EP1009236A4 EP 1009236 A4 EP1009236 A4 EP 1009236A4 EP 98934656 A EP98934656 A EP 98934656A EP 98934656 A EP98934656 A EP 98934656A EP 1009236 A4 EP1009236 A4 EP 1009236A4
Authority
EP
European Patent Office
Prior art keywords
agents
administration
evaluation
treatment
heart disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98934656A
Other languages
English (en)
French (fr)
Other versions
EP1009236A1 (de
Inventor
Roger J Hajjar
Anthony Rosenzweig
Luis Guerrero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Priority to EP03012035A priority Critical patent/EP1374909A3/de
Publication of EP1009236A1 publication Critical patent/EP1009236A1/de
Publication of EP1009236A4 publication Critical patent/EP1009236A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP98934656A 1997-07-22 1998-07-20 Evaluierung, verabreichung und verwendung von mitteln zur behandlung vonherzerkrankungen Withdrawn EP1009236A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP03012035A EP1374909A3 (de) 1997-07-22 1998-07-20 Evaluierung, Verabreichung und Verwendung von Mitteln zur Behandlung von Herzerkrankungen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5335697P 1997-07-22 1997-07-22
US53356P 1997-07-22
PCT/US1998/014968 WO1999004636A1 (en) 1997-07-22 1998-07-20 Evaluation of, delivery of, and use of agents to treat heart disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP03012035A Division EP1374909A3 (de) 1997-07-22 1998-07-20 Evaluierung, Verabreichung und Verwendung von Mitteln zur Behandlung von Herzerkrankungen

Publications (2)

Publication Number Publication Date
EP1009236A1 EP1009236A1 (de) 2000-06-21
EP1009236A4 true EP1009236A4 (de) 2000-10-25

Family

ID=21983650

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98934656A Withdrawn EP1009236A4 (de) 1997-07-22 1998-07-20 Evaluierung, verabreichung und verwendung von mitteln zur behandlung vonherzerkrankungen

Country Status (3)

Country Link
EP (1) EP1009236A4 (de)
CA (1) CA2297328A1 (de)
WO (1) WO1999004636A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063426A2 (en) * 1999-04-15 2000-10-26 Devgen Nv Compound screening methods
DE10126371A1 (de) * 2001-05-30 2003-02-27 Medigene Ag Verfahren zur Identifizierung von Substanzen gegen Herzmuskelzellen-Hypertrophie
WO2005023292A1 (en) 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAJJAR, ROGER J. ET AL: "Modulation of ventricular function through gene transfer in vivo", PROC. NATL. ACAD. SCI. U. S. A. (1998), 95(9), 5251-5256, XP002141696 *
HOIT, B.D. ET AL.: "Influence of transgenic overexpression of phospholamban on postextrasystolic potentation", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 31, no. 11, November 1999 (1999-11-01), pages 2007 - 2015, XP002141698 *
NEUMANN, J. ET AL.: "Targeted overexpression of phospholamban to mouse atrium depresses Ca2+ transport and contractility", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 30, no. 10, October 1998 (1998-10-01), pages 1991 - 2002, XP002141697 *
See also references of WO9904636A1 *

Also Published As

Publication number Publication date
WO1999004636A1 (en) 1999-02-04
EP1009236A1 (de) 2000-06-21
WO1999004636A9 (en) 1999-04-29
CA2297328A1 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
DE69630479D1 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
FI20000720A7 (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
DE69623722D1 (de) Blutbehandlungsgerät
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
EP1173191A4 (de) Neuartige antiangiogenese peptidagenzien sowie ihre therapeutische und diagnostische verwendung
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
PT1233973E (pt) Derivados de adenosina n6-heterociclicos 5'-tio-substituida agonistas parciais ou totais de a1
EP1007048A4 (de) Identifizierung von mitteln zur behandlung der alzheimerischen krankheit
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
DE69603635D1 (de) Katheterstruktur für medizinische Behandlung
MA24332A1 (fr) Utilisation de 1-hydroxy-2- pyridones pour le traitement d'infections de la peau
DE59002510D1 (de) Mittel gegen Keratinschädlinge.
DE69838785D1 (de) Pharmazeutische mittel zur behandlung von zerebralen amyloidosis
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
MA25501A1 (fr) Traitement de l'endometriosis ou de la sterilite ou amelioration de la fertilite.
FR2744361B1 (fr) Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
EP1009236A4 (de) Evaluierung, verabreichung und verwendung von mitteln zur behandlung vonherzerkrankungen
FR2684552B1 (fr) Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
MA26650A1 (fr) Oxo-thia -azabicyclooctenes, preparations pharmaceutiques les contenant, et leur utilisation pour le traitement et la prophylaxie de maladies infectieuses.
EP0990441A4 (de) Arzneimittel zur behandlung von diabetischer nephrosis
EP1224937A4 (de) Stabile präparationen zur behandlung von dekubitus, hautgeschwüre und wunden
FR2759906B1 (fr) Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques
DE68906245D1 (de) Therapeutisches mittel gegen aids.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE ES FR GB LI

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 01N 63/00 A, 7A 01N 43/04 B, 7C 12Q 1/68 B, 7C 12N 15/64 B, 7C 12N 5/00 B, 7C 07H 21/04 B, 7G 01N 33/50 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000907

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE ES FR GB LI

17Q First examination report despatched

Effective date: 20011119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050826